Merck & Co. was the talk of the town in Madrid after signing a multi-billion dollar antibody drug conjugate (ADC) deal with Daiichi Sankyo to open this year’s European Society for Medical Oncology ...
On the cover: In this issue of Cell Genomics, Borbye-Lorenzen et al. examine the correlates of circulating C3 and C4 protein concentrations in 68,768 neonates and the risk of mental and autoimmune ...
Apparently, C4 Therapeutics' protein degradation tech brings all the Mercks to the yard. The Massachusetts biotech has signed on Merck KGaA in a $740 million biobucks partnership to find two degraders ...
Research led by Professor John McGrath from the University of Queensland found that the concentration of the C4 protein, an important part of the immune system, was not associated with risk of mental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results